@article{ff507a55f55e4f198101bcc3a421bbe7,
title = "Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol",
abstract = "Background: Staphylococcus aureus bloodstream infection (bacteremia) is traditionally treated with at least 2 weeks of intravenous (IV) antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia (SAB) with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients. Protocol: The early oral switch (EOS) domain of the S. aureus Network Adaptive Platform (SNAP) trial will assess early switch to oral antibiotics compared with continued IV treatment in clinically stable patients with SAB. The primary endpoint is 90-day all-cause mortality. Hospitalised SAB patients are assessed at platform day 7 ±2 (uncomplicated SAB) and day 14 ±2 (complicated SAB) to determine their eligibility for randomization to EOS (intervention) or continued IV treatment (current standard of care). Discussion: Recruitment is occurring in the EOS domain of the SNAP trial. As of August 2023, 21% of all SNAP participants had been randomized to the EOS domain, a total of 264 participants across 77 centers, with an aim to recruit at least 1000 participants. We describe challenges and facilitators to enrolment in this domain to aid those planning similar trials.",
keywords = "Staphylococcus aureus (or S. aureus), adaptive platform clinical trial, bacteremia (or bacteraemia or bloodstream infection), intravenous antibiotic, oral antibiotic",
author = "{The SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee for the SNAP Trial Group} and {De Kretser}, Dana and Jocelyn Mora and Max Bloomfield and Anita Campbell and Cheng, {Matthew P.} and Stephen Guy and Marjolein Hensgens and Shirin Kalimuddin and Lee, {Todd C.} and Amy Legg and Mahar, {Robert K.} and Michael Marks and Julie Marsh and Anna McGlothin and Morpeth, {Susan C.} and Archana Sud and {Ten Oever}, Jaap and Dafna Yahav and Marc Bonten and Bowen, {Asha C.} and Nick Daneman and {Van Hal}, {Sebastiaan J.} and Heriot, {George S.} and Lewis, {Roger J.} and Lye, {David C.} and Zoe McQuilten and Paterson, {David L.} and {Owen Robinson}, J. and Roberts, {Jason A.} and Matthew Scarborough and Webb, {Steve A.} and Lynda Whiteway and Tong, {Steven Y.C.} and Davis, {Joshua S.} and Genevieve Walls and Goodman, {Anna L.} and J. Marsh and Tong, {S. Y.C.} and Davis, {J. S.} and Goodman, {A. L.} and G. Walls and Morpeth, {S. C.} and M. Hensgens and J. Mora and D. Yahav and A. McGlothlin and Cheng, {M. P.} and Nick Anagnostou and Sophia Acrhuleta and Eugene Athan",
note = "Publisher Copyright: {\textcopyright} 2023 The Author(s).",
year = "2024",
month = oct,
day = "15",
doi = "10.1093/cid/ciad666",
language = "אנגלית",
volume = "79",
pages = "871--887",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",
}